Bone Health in Men with Prostate Cancer: Review Article
Autor: | Abdulazeez Salawu, Janet E. Brown, Salma El Badri |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Oncology
Male medicine.medical_specialty Antineoplastic Agents Hormonal Endocrinology Diabetes and Metabolism Osteoporosis Bone Neoplasms Androgen deprivation therapy Bone health Gonadotropin-Releasing Hormone 03 medical and health sciences Prostate cancer 0302 clinical medicine Bone Density Internal medicine Epidemiology Advanced disease Medicine Humans 030212 general & internal medicine Cancer-induced Musculoskeletal Diseases (E Keller and J Sterling Section Editors) Bone Resorption Glucocorticoids business.industry Cancer Prostatic Neoplasms Androgen Antagonists medicine.disease Review article Bone Diseases Metabolic Prostatic Neoplasms Castration-Resistant 030220 oncology & carcinogenesis business Orchiectomy Osteoporotic Fractures |
Zdroj: | Current Osteoporosis Reports |
ISSN: | 1544-2241 1544-1873 |
Popis: | Purpose of Review The improvement in prostate cancer survival over time, even in those with advanced disease, has led to an increasing recognition of the impact of prostate cancer and its treatment on bone health. Cancer treatment–induced bone loss (CTIBL) is a well-recognized entity but greater awareness of the risks associated with CTIBL and its treatment is required. Recent Findings The principal culprit in causing CTIBL is hormonal ablation induced by prostate cancer treatment, including several new agents which have been developed in recent years which significantly improve survival, but may cause CTIBL. This review discusses the impact of prostate cancer and its treatment on bone health, including published evidence on the underlying pathophysiology, assessment of bone health, and strategies for prevention and treatment. Summary It is important to recognize the potential cumulative impact of systemic prostate cancer treatments on bone health. |
Databáze: | OpenAIRE |
Externí odkaz: |